Article

Targeting EphA2 and DDR signaling can overcome the BRAF and MEK inhibitors acquired resistance in melanoma cell lines

2022-10-17

Abstract excerpt

<title>Abstract</title> <p>The BRAF and MEK inhibitors combined strategies have dramatically changed the outcome of BRAF-mutated metastatic melanoma patients. However, despite the initial promising results, the onset of primary or acquired resistance occurs in nearly half of the patients at about 1 year from the diagnosis. Understanding the mechanisms of resistance to these inhibitors is therefore critical for pl...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 545cd221-0498-5cb9-aaf2-44447fe2651c
DOI: 10.21203/rs.3.rs-2154654/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Targeting EphA2 and DDR signaling can overcome the BRAF and MEK inhibitors acquired resistance in melanoma cell linesDOI 10.21203/rs.3.rs-2154654/v1Read

Analysis of BRAF inhibitor resistance in melanoma cellsSemantic proximity Read

Targeted therapy in BRAF‑mutant melanoma: Advances and challenges (Review).Semantic proximity Read

Overcoming resistance to BRAF inhibitorsSemantic proximity Read

Detecting mechanisms of acquired BRAF inhibitor resistance in melanoma.Semantic proximity Read

BRAF Inhibitor Resistance in Melanoma: Mechanisms and Alternative Therapeutic Strategies.Semantic proximity Read

BRAF V600-Mutated Metastatic Melanoma and Targeted Therapy Resistance: An Update of the Current KnowledgeSemantic proximity Read

Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanomaSemantic proximity Read

Advances in Understanding Drug Resistance Mechanisms and Innovative Clinical Treatments for Melanoma.Semantic proximity Read

A Review of the Molecular Pathways Involved in Resistance to BRAF Inhibitors in Patients with Advanced-Stage Melanoma.Semantic proximity Read

Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant CancersSemantic proximity Read

Strategies for Overcoming Resistance in Tumours Harboring BRAF Mutations.Semantic proximity Read

[Mechanisms of resistance to anti-BRAF treatments].Semantic proximity Read